. 2006 Mar 26;6:81. doi: 10.1186/1471-2407-6-81

Table 2.

Mean tumour marker levels during fulvestrant treatment

Patient response	mean marker levels (+/- SD) (month)
	1	2	3	4	5	6	7	8	9
				P-values (1→4 months)		P-values (1→6 months)
PR (n = 7)
CA 15-3	144.00	128.54	156.87	178.16	170.19	197.01
(kU/l)	+/-171.75	+/-164.90	+/-194.54	+/-227.42	+/-256.43	+/-270.54
				N.S.		N.S.
CEA	5.31	4.17	3.87	3.81	3.46	4.06
(μg/l)	+/-3.96	+/-2.82	+/-2.61	+/-2.54	+/-2.78	+/-2.95
				N.S.		0.0165
SD ≥ 6 months (n = 28)
CA 15-3	184.68	214.00	226.54	240.64	269.05	268.61
(kU/l)	/-214.08	+/-262.54	+/-297.58	+/-305.39	+/-352.19	+/-338.27
				0.0023		< 0.0001
CEA	52.59	43.63	43.49	58.01	55.28	72.70
(μg/l)	+/-201.99	+/-153.74	+/-153.73	+/-224.58	+/-203.94	+/-307.61
				N.S.		0.0399
SD ≥ 6 < 9 months (n = 14)
CA 15-3	205.21	232.21	265.50	281.07	302.71	309.04
(kU/l)	+/-256.19	+/-309.81	+/-378.08	+/-378.57	+/-424.97	+/-429.82
				0.0017		0.0002
SD ≥ 9 months (n = 14)
CA 15-3	164.14	195.79	185.57	200.21	214.50	229.07	209.55	258.61	263.29
(kU/l)	+/-169.24	+/-215.55	+/-194.18	+/-216.47	+/-229.92	+/-263.48	+/-226.84	+/-283.62	+/-292.21
				0.0405		0.0146
De novo PD (n = 32)
CA 15-3	259.91	419.41	441.16	580.31
(kU/l)	+/-419.29	+/-994.42	+/-790.95	+/-1052.69
				< 0.0001
CEA	140.61	192.37	199.98	250.09
(μg/l)	+/-652.01	+/-902.53	+/-907.67	+/-1087.32
				0.0002
Secondary PD (n = 28)
CA 15-3	411.20^a	510.67^b	572.50^c	698.72^d
(kU/l)	+/-541.50	+/-834.03	+/-891.17	+/-1164.36
				< 0.0001
CEA	56.32 ^a	53.46 ^b	69.99 ^b	110.32 ^d
(μg/l)	+/-224.80	+/-203.92	+/-269.53	+/-473.03
				< 0.0001

PR, partial response; SD, stable disease; PD, disease progression; NS, not statistically significant; ^a2 months before PD; ^b1 months before PD; ^cPD; ^d1 month after PD